- Home
- COLL vs KRP Comparison
COLL vs KRP Comparison
Compare COLL & KRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- KRP
- Stock Information
- Founded
- COLL 2002
- KRP 2013
- Country
- COLL United States
- KRP United States
- Employees
- COLL N/A
- KRP N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- KRP Oil & Gas Production
- Sector
- COLL Health Care
- KRP Energy
- Exchange
- COLL Nasdaq
- KRP Nasdaq
- Market Cap
- COLL 958.8M
- KRP 1.1B
- IPO Year
- COLL 2015
- KRP 2017
- Fundamental
- Price
- COLL $30.35
- KRP $14.15
- Analyst Decision
- COLL Strong Buy
- KRP Hold
- Analyst Count
- COLL 4
- KRP 5
- Target Price
- COLL $43.75
- KRP $17.40
- AVG Volume (30 Days)
- COLL 283.6K
- KRP 572.3K
- Earning Date
- COLL 08-07-2025
- KRP 08-07-2025
- Dividend Yield
- COLL N/A
- KRP 12.15%
- EPS Growth
- COLL N/A
- KRP N/A
- EPS
- COLL 1.25
- KRP 0.07
- Revenue
- COLL $664,283,000.00
- KRP $312,876,555.00
- Revenue This Year
- COLL $20.04
- KRP $10.45
- Revenue Next Year
- COLL $3.98
- KRP $3.27
- P/E Ratio
- COLL $24.19
- KRP $194.89
- Revenue Growth
- COLL 17.17
- KRP 3.03
- 52 Week Low
- COLL $23.23
- KRP $10.98
- 52 Week High
- COLL $42.29
- KRP $17.07
- Technical
- Relative Strength Index (RSI)
- COLL 54.25
- KRP 59.98
- Support Level
- COLL $29.28
- KRP $13.72
- Resistance Level
- COLL $30.83
- KRP $14.12
- Average True Range (ATR)
- COLL 0.75
- KRP 0.29
- MACD
- COLL -0.00
- KRP -0.04
- Stochastic Oscillator
- COLL 51.63
- KRP 42.80
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About KRP Kimbell Royalty Partners Common Units Representing Limited Partner Interests
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.